Reata Pharmaceuticals, Inc. (RETA)
(Delayed Data from NSDQ)
$80.41 USD
+2.31 (2.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $80.37 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RETA 80.41 +2.31(2.96%)
Will RETA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RETA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RETA
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
RETA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates
Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates